Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Is ctDNA a good biomarker for advanced prostate cancer?

Vincenza Conteduca • 15 Feb 2022
GU Cancers 2022
Genitourinary Cancer Prostate Cancer

Vincenza Conteduca, MD, PhD, Scientific Institute of Romagna for the Study and Treatment of Tumors, Meldola, Italy, discusses the potential of ctDNA as a biomarker for advanced prostate cancer. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

Disclosures

V.C. has served as consultant/advisory board member for Janssen, Astellas, Merck, AstraZeneca, Bayer, BMS; has received speaker honoraria or travel support from Astellas, Janssen, Ipsen, Bayer and Sanofi.

More from Vincenza Conteduca

ctDNA level variation as an early predictor of survival in patients with mCRPC
3:42
ctDNA level variation as an early predictor of survival in patients with mCRPC
Vincenza Conteduca • 15 Feb 2022

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals